LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI)...

Annals of Oncology 2020 / 09 Vol. 31

LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA

Reck, M., Ciuleanu, T-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Cheng, Y., Paz-Ares, L., Lu, S., John, T., Padilla, B., Sun, X., Moisei, A., Yan, J., Yuan, Y.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.2292
Date:
September, 2020
File:
PDF, 124 KB
2020
Conversion to is in progress
Conversion to is failed